Market Overview

Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation

Share:
Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation
Related STML
25 Stocks Moving In Wednesday's Pre-Market Session
55 Biggest Movers From Yesterday

Stemline Therapeutics Inc (NASDAQ: STML) has received FDA approved for Elzonris ahead of the Feb. 21 PDUFA date. The approval coming in two months early highlights “the urgent need” in the indication, according to H.C. Wainwright.

The Analyst

Analyst Raghuram Selvaraju initiated coverage of Stemline Therapeutics with a Buy rating and $38 price target.

The Thesis

The FDA has approved Elzonris infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm, or BPDCN, in adults and in pediatric patients 2 and up, Selvaraju said in the Wednesday initiation note. 

Not only does this represent the first therapy to be approved for BPDCN, it has been approved for treatment-naïve — first-line — patients as well as relapsed or refractory patients who have received intensive chemotherapy, the analyst said. 

It is unlikely that the boxed warning on Elzonris’ prescription label regarding the increased risk of capillary leak syndrome will deter physicians from prescribing BPDCN patients with the drug, since CLS is largely cycle 1-related and manageable with monitoring and pre-emptive measures, as mentioned at the American Society of Hematology 2018 meeting, Selvaraju said.

With Stemline indicating that the planned launch of Elzonris in early 2019 is on track, the probability of success has increased from 90 percent to 100 percent, the analyst said. 

H.C Wainwright increased its annual price estimate for Elzonris from $350,000 to $400,000. 

Price Action

Stemline Therapeutics were trading higher by 5.91 percent at $8.78 at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

FDA Approves First Treatment for Rare Blood Disease

Latest Ratings for STML

DateFirmActionFromTo
Dec 2018JP MorganInitiates Coverage OnOverweight
Nov 2018PiperJaffrayInitiates Coverage OnOverweight
May 2018WedbushMaintainsOutperformOutperform

View More Analyst Ratings for STML
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Price Target Initiation FDA Analyst Ratings General Best of Benzinga

 

Related Articles (STML)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MDRXKeyBancUpgrades0.0
ANETNomuraUpgrades260.0
CNPRBC CapitalUpgrades34.0
FISVOppenheimerUpgrades88.0
FNDUBSUpgrades37.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Media Mogul Gary Vaynerchuk to Speak at Transparency19

Blizzard, Severe Thunderstorms To Disrupt Returning Holiday Travelers